TSH and the Aging Thyroid: When a Higher Number Is Not a Disease

Key Takeaways:

• In a US national survey of people without thyroid disease, the upper limit of TSH (the 97.5th percentile) rose from 3.56 mIU/L in adults aged 20 to 29 to 7.49 mIU/L in those 80 and older, and 70 percent of older adults with a TSH above 4.5 were within their age-specific range.
• In the TRUST trial of 737 adults aged 65 and older with persistent subclinical hypothyroidism, levothyroxine lowered TSH but produced no difference from placebo in hypothyroid symptoms or tiredness after one year.
• Subclinical hypothyroidism means a raised TSH with a normal free T4; the trial evidence against routine treatment in older adults applies to mild elevations, not to a low free T4, very high TSH, or pregnancy.

Thyroid-stimulating hormone, or TSH, is the pituitary’s request for more thyroid hormone. When the gland lags, the pituitary asks louder and TSH climbs, which is why TSH is such a sensitive screening test. But the relationship between TSH and aging is not the one most lab reports assume. A single reference range, usually topping out around 4.5, is printed next to the result whether the patient is twenty-five or eighty-five. When investigators analyzed a large US national survey and set aside everyone with known thyroid disease, the whole distribution of TSH slid upward decade by decade. Only about one in ten healthy adults in their twenties had a TSH above 2.5; in the 80-and-older group it was four in ten. The 97.5th percentile, the practical upper limit of normal, nearly doubled, from 3.56 to 7.49. Seventy percent of the older adults who would be flagged as high on a standard report were sitting comfortably inside the range for their own age. A longitudinal study following the same people for thirteen years found the same thing from the inside: mean TSH rose while free T4, the hormone the gland actually delivers, did not change at all.

That pattern, a higher request with an unchanged delivery, looks less like failure and more like a resetting of the set point. The outcome data point the same way. In a population-based study of people followed from age 85, higher TSH was not associated with more disability, depression, or cognitive decline, and it was associated with lower mortality, a hazard ratio of 0.77 for each standard-deviation rise. Observational findings can mislead, so the definitive test was a randomized trial. The TRUST trial enrolled 737 adults aged 65 and older whose TSH was persistently between 4.60 and 19.99 with a normal free T4, a mean of 6.40, and assigned them to levothyroxine or placebo with dose adjustment. The drug did its biochemical job, bringing TSH down to 3.63, yet after a year the change in hypothyroid symptom scores was identical in both groups, and tiredness scores differed by less than half a point on a hundred-point scale. A prospectively planned analysis of adults 80 and older found no benefit either.

How should TSH and aging change the way results are read?

It starts with patience. Nearly every mildly high TSH deserves a repeat measurement, with free T4, before anything is decided; in TRUST, TSH drifted down on its own from 6.40 to 5.48 in the placebo group over a single year. If free T4 is normal and TSH sits in the single digits, the evidence from older adults argues for watching rather than prescribing, and many people who began levothyroxine for a borderline number deserve a thoughtful conversation about whether it is still doing anything for them. The limits of that evidence matter just as much. TRUST included few people with TSH of 10 or higher, so these results do not settle what to do at that level, and they say nothing about a low free T4, which is true hypothyroidism at any age. Pregnancy, younger adults, and people with thyroid antibodies and rising values each call for their own judgment. The practical rule is simple: a TSH result is interpreted against the person, their age, their free T4, and its trend over time, not against a single line printed on a lab report. Reading it that way spares many older adults a daily pill that trials show does not make them feel better.

References:

1. Surks, M. I., & Hollowell, J. G. (2007). Age-specific distribution of serum thyrotropin and antithyroid antibodies in the US population: Implications for the prevalence of subclinical hypothyroidism. The Journal of Clinical Endocrinology and Metabolism, 92(12), 4575-4582.
2. Bremner, A. P., Feddema, P., Leedman, P. J., Brown, S. J., Beilby, J. P., Lim, E. M., et al. (2012). Age-related changes in thyroid function: A longitudinal study of a community-based cohort. The Journal of Clinical Endocrinology and Metabolism, 97(5), 1554-1562.
3. Gussekloo, J., van Exel, E., de Craen, A. J., Meinders, A. E., Frölich, M., & Westendorp, R. G. (2004). Thyroid status, disability and cognitive function, and survival in old age. JAMA, 292(21), 2591-2599.
4. Stott, D. J., Rodondi, N., Kearney, P. M., Ford, I., Westendorp, R. G. J., Mooijaart, S. P., et al. (2017). Thyroid hormone therapy for older adults with subclinical hypothyroidism. The New England Journal of Medicine, 376(26), 2534-2544.
5. Mooijaart, S. P., Du Puy, R. S., Stott, D. J., Kearney, P. M., Rodondi, N., Westendorp, R. G. J., et al. (2019). Association between levothyroxine treatment and thyroid-related symptoms among adults aged 80 years and older with subclinical hypothyroidism. JAMA, 322(20), 1977-1986.